Login to Your Account

Diamyd Stock Plunges 85% on Phase III Diabetes Miss

By Cormac Sheridan

Tuesday, May 10, 2011
Shares in Diamyd AB plunged 85 percent Monday on news that its immunotherapy treatment for Type I diabetes, also called Diamyd, missed the primary endpoint of a European Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription